Regeneron Pharmaceuticals, Inc. (LON:0R2M)
London
· Delayed Price · Currency is GBP · Price in USD 700.68
+4.42 (0.63%)
At close: Feb 21, 2025
Regeneron Pharmaceuticals Revenue
In the year 2024, Regeneron Pharmaceuticals had annual revenue of $14.20B USD with 8.27% growth. Regeneron Pharmaceuticals had revenue of $3.79B in the quarter ending December 31, 2024, with 10.33% growth.
Revenue
$14.20B
Revenue Growth
+8.27%
P/S Ratio
n/a
Revenue / Employee
$940.16K
Employees
15,106
Market Cap
59.29B GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 14.20B | 1.08B | 8.27% |
| Dec 31, 2023 | 13.12B | 944.30M | 7.76% |
| Dec 31, 2022 | 12.17B | -3.90B | -24.26% |
| Dec 31, 2021 | 16.07B | 7.57B | 89.14% |
| Dec 31, 2020 | 8.50B | 1.94B | 29.58% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| AstraZeneca | 43.19B |
| GSK plc | 31.38B |
| Haleon | 11.24B |
| Smith & Nephew | 4.46B |
| Hikma Pharmaceuticals | 2.39B |
| ConvaTec Group | 1.74B |
| HUTCHMED (China) | 483.31M |
| Genus | 668.80M |
Regeneron Pharmaceuticals News
- 1 day ago - The Schall Law Firm Invites Investors With Losses To Join A Securities Fraud Case Against Regeneron Pharmaceuticals, Inc. - Accesswire
- 1 day ago - ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Regeneron Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - REGN - Accesswire
- 1 day ago - Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Regeneron Pharmaceuticals, Inc. (REGN) Shareholders - Accesswire
- 1 day ago - ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Regeneron Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - REGN - Accesswire
- 1 day ago - Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights - REGN - Accesswire
- 1 day ago - Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky for More Information – REGN - GlobeNewsWire
- 1 day ago - Regeneron Pharmaceuticals (REGN) Faces Mounting Pressure on Sales, Legal Fronts – Hagens Berman - GlobeNewsWire
- 1 day ago - Shareholders that lost money on Regeneron Pharmaceuticals, Inc. (REGN) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More - Accesswire